Drug Search Results
More Filters [+]

Pyrimethamine

Alternative Names: pyrimethamine, daraprim, pyrimethamin, maloprim, fansidar
Latest Update: 2024-10-12
Latest Update Note: Clinical Trial Update

Product Description

Pyrimethamine is an antiparasitic prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of Toxoplasma gondiiinfection (toxoplasmosis). Pyrimethamine is usually used together with a sulfonamide (sulfa medicine) to treat toxoplasmosis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimethamine)

Mechanisms of Action: DHFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | India | Indonesia | Ireland | Italy | Jordan | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Slovenia | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Thailand | United Kingdom | United States | Uruguay | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pyrimethamine

Countries in Clinic: Jordan, Kenya, Uganda

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Malaria

Phase 2: Bladder Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Malaria, Falciparum|Melanoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Prostate Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer|Triple Negative Breast Cancer

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CHMI-TransMod

P2

Suspended

Malaria, Falciparum

2025-12-01

SUPY-T005

P1

Not yet recruiting

Healthy Volunteers

2024-08-01

DPSP

P3

Completed

Malaria

2024-07-28

2017-005057-36

P2

Active, not recruiting

Small Cell Lung Cancer|Triple Negative Breast Cancer|Melanoma|Prostate Cancer|Renal Cell Carcinoma|Esophageal Cancer|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Bladder Cancer|Colorectal Cancer|Ovarian Cancer|Head and Neck Cancer

2018-11-23

Recent News Events